This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

InspireMD To Host Symposium On MGuard™ At EuroPCR In Paris

TEL AVIV, Israel, May 10, 2012 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, will host a symposium and cocktail reception at the EuroPCR meeting on Wednesday, May 16 in Paris.

Results from the EF (extended follow up) MAGICAL trial will be presented for the first time at this symposium.  This is a retrospective analysis of the MAGICAL trial population with follow-up duration of 3 years.  MAGICAL was a prospective, single arm study that enrolled 60 STEMI patients with less than 12 hours symptom onset. Primary endpoints were ST segment resolution, TIMI flow and Blush score. The data from the EF MAGICAL trial will be presented by the principal investigator, Dr. Dariusz Dudek from the Jagiellonian University, Krakow, Poland.

The symposium will also feature the first European presentation of the MICAMI trial, which is the first prospective randomized study with MGuard™, that demonstrated a statistically significant improvement in acute outcomes in STEMI patients when compared with traditional bare metal stents (BMS).  This data was presented earlier this year in Washington, D.C. by principal investigator Dr. Dante Lindefjeld from the Pontifical Catholic University of Chile, Santiago, Chile.

The symposium "Thrombus Management in STEMI: MGuard Late Breaking Data" will take place at Concorde Lafayette Hotel (Grande Etoile D'Or Hall) in Paris on Wednesday May 16, from 6.30 – 8 PM.

About EuroPCR

EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions. It serves as one of the leading international courses in Interventional Medicine.  It will take place this year in Paris, France May 15 – 18. More than 12,000 participants from around the world are expected to attend.

About MGuard Coronary Stent

MGuard™ combines a coronary stent merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that wraps the stent. The MGuard™ stent seeks to provide outstanding and lifelong embolic protection, without affecting deliverability. MGuard™ is CE Mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC).

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,255.17 -30.57 -0.17%
S&P 500 2,128.10 -2.72 -0.13%
NASDAQ 5,093.8960 +3.1020 0.06%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs